Effect of 26 Weeks of Liraglutide Treatment on Coronary Artery Inflammation in Type 2 Diabetes Quantified by [64Cu]Cu-DOTATATE PET/CT: Results from the LIRAFLAME Trial

BackgroundQuantification of coronary artery inflammation and atherosclerosis remains a challenge in high-risk individuals. In this study we sought to investigate if the glucagon like peptide-1 receptor agonist liraglutide has a direct anti-inflammatory effect in the coronary arteries using positron...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Jacob K. Jensen, Emilie H. Zobel, Bernt J. von Scholten, Viktor Rotbain Curovic, Tine W. Hansen, Peter Rossing, Andreas Kjaer, Rasmus S. Ripa
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
PET
Acceso en línea:https://doaj.org/article/85c1b16bc6ce4583a9afe49ce90637c0
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares